Creative Planning
OVID icon

Creative Planning’s Ovid Therapeutics OVID Stock Holding History

Creative Planning’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,932
Closed -$50K – 2181
2021
Q3 		$50K Sell
14,932
-100
-0.7% -$365 ﹤0.01% 1994
2021
Q2 		$59K Sell
15,032
-50
-0.3% -$197 ﹤0.01% 1926
2021
Q1 		$61K Buy
15,082
+100
+0.7% +$332 ﹤0.01% 2326
2020
Q4 		$35K Hold
14,982
– – ﹤0.01% 2136
2020
Q3 		$86K Sell
14,982
-2,250
-13% -$15.1K ﹤0.01% 1847
2020
Q2 		$127K Buy
17,232
+1,700
+11% +$7.95K ﹤0.01% 1623
2020
Q1 		$46K Hold
15,532
– – ﹤0.01% 1644
2019
Q4 		$64K Buy
15,532
+600
+4% +$1.9K ﹤0.01% 1797
2019
Q3 		$48K Hold
14,932
– – ﹤0.01% 1792
2019
Q2 		$28K Hold
14,932
– – ﹤0.01% 1864
2019
Q1 		$26K Hold
14,932
– – ﹤0.01% 1826
2018
Q4 		$36K Hold
14,932
– – ﹤0.01% 1747
2018
Q3 		$85K Hold
14,932
– – ﹤0.01% 1815
2018
Q2 		$116K Hold
14,932
– – ﹤0.01% 1744
2018
Q1 		$106K Buy
+14,932
New +$121K ﹤0.01% 1740

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Creative Planning's OVID Position: Q4 2021 in Review

Creative Planning sold out of Ovid Therapeutics (OVID) in Q4 2021, closing a stake of 14,932 shares — an estimated $50K sold.

Creative Planning first reported a position in OVID in Q1 2018 and held it in 15 quarters. The position peaked at $127K in Q2 2020. 67 funds tracked by Wall St. Rank hold OVID as of Q4 2021.

  • Creative Planning reported no remaining Ovid Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Creative Planning sold 14,932 Ovid Therapeutics shares in Q4 2021, an estimated $50K.
  • Creative Planning first reported a position in Ovid Therapeutics in Q1 2018 and held it in 15 quarters.
  • Creative Planning's Ovid Therapeutics position peaked at $127K in Q2 2020.
  • 67 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2021.

Based on Creative Planning's 13F filing for Q4 2021, filed 11 Feb 2022.